{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T04:06:30Z","timestamp":1748664390034,"version":"3.41.0"},"reference-count":38,"publisher":"Societatea Romana de Morfologie","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rom J Morphol Embryol"],"published-print":{"date-parts":[[2025,5,23]]},"abstract":"<jats:p>Background: Surgery is the standard therapy for pancreatic neuroendocrine tumors (pNETs), but since post-resection fistulae and other surgery related complications are common, new minimal invasive approaches are emerging. Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is a promising tool for pNETs, with a good safety profile and favorable results. Patients, Materials and Methods: This is a single-center, retrospective case series including all patients with functional (F) and non-functional (NF) pNETs treated with EUS-RFA in the Department of Gastroenterology, Emergency Clinical Hospital of Bucharest, Romania, between March 2023 and March 2024 and followed for a mean period of 11.6 months. Technical success, clinical, sonographic and radiological response, adverse events (AEs) rate and severity were assessed. Case series: A total of five out of nine EUS-RFA were performed for pNETs, with a majority of NF-pNETs. In this pNET group, the mean size of the lesions was 13 mm. Technical success was achieved in 100% of patients and persistent clinical remission of hypoglycemia in the insulinoma case was attained. In the NF-pNET subgroup, two patients were successfully radiologically treated with complete disappearance of the lesions, one lesion showed cystic transformation, and one had modest size reduction at follow-up imagery. One procedure-related early AE occurred: mild abdominal pain with quick resolution. No major complications, nor death were reported. Conclusions: Reports from this literature review and small case series suggest that EUS-RFA can be effective in both F- and NF-pNETs, offering the best combination of real-time imaging guidance and minimal invasiveness with no severe AEs and short hospital stay.<\/jats:p>","DOI":"10.47162\/rjme.66.1.02","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T08:40:16Z","timestamp":1748594416000},"page":"31-38","source":"Crossref","is-referenced-by-count":0,"title":["Pancreatic neuroendocrine tumors \u2013 going beyond surgery. Literature review and experience of a tertiary center"],"prefix":"10.47162","volume":"66","author":[{"name":"Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Department of Gastroenterology, Fundeni Clinical Institute, Bucharest, Romania","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rucsandra-Ilinca","family":"Diculescu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u0103d\u0103lina","family":"Stan-Ilie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Department of Gastroenterology, Emergency Clinical Hospital of Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher Jesse Vlad","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Department of Gastroenterology, Emergency Clinical Hospital of Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oana-Mihaela","family":"Plotogea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Department of Gastroenterology, Emergency Clinical Hospital of Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Constantinescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Department of Gastroenterology, Emergency Clinical Hospital of Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasile","family":"\u015eandru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Department of Gastroenterology, Emergency Clinical Hospital of Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doina","family":"Istr\u0103tescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Department of Gastroenterology, Fundeni Clinical Institute, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeriu Bogdan","family":"Popa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Department of Radiology and Medical Imaging, Emergency Clinical Hospital of Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentin","family":"Enache","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Pathology, Emergency Clinical Hospital of Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u0103ndica Nicoleta","family":"Bucuric\u0103","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Department of Gastroenterology, Dr. Carol Davila Central Military Emergency University Hospital, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u0103t\u0103lina","family":"Poian\u0103","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Department of Endocrinology, C. I. Parhon National Institute of Endocrinology, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"26736","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"\"[1] Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol, 2017, 3(10):1335-1342. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0589","DOI":"10.1001\/jamaoncol.2017.0589"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"[2] Pole\u00e9 IN, Hermans BCM, van der Zwan JM, Bouwense SAW, Dercksen MW, Eskens FALM, Havekes B, Hofland J, Kerkhofs TMA, Kl\u00fcmpen HJ, Latten-Jansen LM, Speel EJM, Verburg FA, Walenkamp AME, Geurts SME, de Vos-Geelen J. Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: a population-based study. Eur J Cancer, 2022, 172:252-263. https:\/\/doi.org\/10.1016\/j.ejca.2022.06.003","DOI":"10.1016\/j.ejca.2022.06.003"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"[3] Yang Z, Shi G. Comparative outcomes of pancreatic neuroendocrine neoplasms: a population-based analysis of the SEER database. Eur J Surg Oncol, 2022, 48(10):2181-2187. https:\/\/doi.org\/10.1016\/j.ejso.2022.05.016","DOI":"10.1016\/j.ejso.2022.05.016"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"[4] Kasumova GG, Tabatabaie O, Eskander MF, Tadikonda A, Ng SC, Tseng JF. National rise of primary pancreatic carcinoid tumors: comparison to functional and nonfunctional pancreatic neuroendocrine tumors. J Am Coll Surg, 2017, 224(6):1057-1064. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2016.11.014","DOI":"10.1016\/j.jamcollsurg.2016.11.014"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"[5] Kos-Kud\u0142a B, Casta\u00f1o JP, Denecke T, Grande E, Kjaer A, Koumarianou A, de Mestier L, Partelli S, Perren A, St\u00e4ttner S, Valle JW, Fazio N. European Neuroendocrine Tumour Society (ENETS) 2023 Guidance Paper for nonfunctioning pancreatic neuroendocrine tumours. J Neuroendocrinol, 2023, 35(12):e13343. https:\/\/doi.org\/10.1111\/jne.13343","DOI":"10.1111\/jne.13343"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"[6] Howe JR, Merchant NB, Conrad C, Keutgen XM, Hallet J, Drebin JA, Minter RM, Lairmore TC, Tseng JF, Zeh HJ, Libutti SK, Singh G, Lee JE, Hope TA, Kim MK, Menda Y, Halfdanarson TR, Chan JA, Pommier RF. The North American Neuroendocrine Tumor Society Consensus Paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas, 2020, 49(1):1-33. https:\/\/doi.org\/10.1097\/MPA.0000000000001454","DOI":"10.1097\/MPA.0000000000001454"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"[7] Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol, 2008, 26(18):3063-3072. https:\/\/doi.org\/10.1200\/JCO.2007.15.4377","DOI":"10.1200\/JCO.2007.15.4377"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"[8] Shin JJ, Gorden P, Libutti SK. Insulinoma: pathophysiology, localization and management. Future Oncol, 2010, 6(2):229-237. https:\/\/doi.org\/10.2217\/fon.09.165","DOI":"10.2217\/fon.09.165"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"[9] Beger HG, Mayer B, Poch B. Duodenum-preserving pancreatic head resection for benign and premalignant tumors - a systematic review and meta-analysis of surgery-associated morbidity. J Gastrointest Surg, 2023, 27(11):2611-2627. https:\/\/doi.org\/10.1007\/s11605-023-05789-4","DOI":"10.1007\/s11605-023-05789-4"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"[10] Kar P, Price P, Sawers S, Bhattacharya S, Reznek RH, Grossman AB. Insulinomas may present with normoglycemia after prolonged fasting but glucose-stimulated hypoglycemia. J Clin Endocrinol Metab, 2006, 91(12):4733-4736. https:\/\/doi.org\/10.1210\/jc.2006-1430","DOI":"10.1210\/jc.2006-1430"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"[11] Nikfarjam M, Warshaw AL, Axelrod L, Deshpande V, Thayer SP, Ferrone CR, Fern\u00e1ndez-del Castillo C. Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital. Ann Surg, 2008, 247(1):165-172. https:\/\/doi.org\/10.1097\/SLA.0b013e31815792ed","DOI":"10.1097\/SLA.0b013e31815792ed"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"[12] Sada A, Yamashita TS, Glasgow AE, Habermann EB, Thompson GB, Lyden ML, Dy BM, Halfdanarson TR, Vella A, McKenzie TJ. Comparison of benign and malignant insulinoma. Am J Surg, 2021, 221(2):437-447. https:\/\/doi.org\/10.1016\/j.amjsurg.2020.08.003","DOI":"10.1016\/j.amjsurg.2020.08.003"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"[13] Landoni L, Marchegiani G, Pollini T, Cingarlini S, D'Onofrio M, Capelli P, De Robertis R, Dav\u00ec MV, Amodio A, Impellizzeri H, Malpaga A, Miotto M, Boninsegna L, Crepaz L, Nessi C, Zingaretti CC, Paiella S, Esposito A, Casetti L, Malleo G, Tuveri M, Butturini G, Salvia R, Scarpa A, Falconi M, Bassi C. The evolution of surgical strategies for pancreatic neuroendocrine tumors (Pan-NENs): time-trend and outcome analysis from 587 consecutive resections at a high-volume institution. Ann Surg, 2019, 269(4):725-732. https:\/\/doi.org\/10.1097\/SLA.0000000000002594","DOI":"10.1097\/SLA.0000000000002594"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"[14] Beger HG, Mayer B, Vasilescu C, Poch B. Long-term metabolic morbidity and steatohepatosis following standard pancreatic resections and parenchyma-sparing, local extirpations for benign tumor: a systematic review and meta-analysis. Ann Surg, 2022, 275(1):54-66. https:\/\/doi.org\/10.1097\/SLA.0000000000004757","DOI":"10.1097\/SLA.0000000000004757"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"[15] Gao RY, Wu BH, Shen XY, Peng TL, Li DF, Wei C, Yu ZC, Luo MH, Xiong F, Wang LS, Yao J. Overlooked risk for needle tract seeding following endoscopic ultrasound-guided minimally invasive tissue acquisition. World J Gastroenterol, 2020, 26(40):6182-6194. https:\/\/doi.org\/10.3748\/wjg.v26.i40.6182","DOI":"10.3748\/wjg.v26.i40.6182"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"[16] Melita G, Pallio S, Tortora A, Crin\u00f2 SF, Macr\u00ec A, Dionigi G. Diagnostic and interventional role of endoscopic ultrasonography for the management of pancreatic neuroendocrine neoplasms. J Clin Med, 2021, 10(12):2638. https:\/\/doi.org\/10.3390\/jcm10122638","DOI":"10.3390\/jcm10122638"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"[17] Karaisz FG, Elkelany OO, Davies B, Lozanski G, Krishna SG. A review on endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) of pancreatic lesions. Diagnostics (Basel), 2023, 13(3):536. https:\/\/doi.org\/10.3390\/diagnostics13030536","DOI":"10.3390\/diagnostics13030536"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"[18] Ahmed M, Goldberg SN. Image-guided tumor ablation: basic science. In: vanSonnenberg E, McMullen WN, Solbiati L, Livraghi T, M\u00fceller PR, Silverman SG (eds). Tumor ablation: principles and practice. 1st edition, Springer Science & Business Media, Berlin-Heidelberg, Germany, 2005, 27. https:\/\/doi.org\/10.1007\/0-387-28674-8_3","DOI":"10.1007\/0-387-28674-8_3"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"[19] Giardino A, Innamorati G, Ugel S, Perbellini O, Girelli R, Frigerio I, Regi P, Scopelliti F, Butturini G, Paiella S, Bacchion M, Bassi C. Immunomodulation after radiofrequency ablation of locally advanced pancreatic cancer by monitoring the immune response in 10 patients. Pancreatology, 2017, 17(6):962-966. https:\/\/doi.org\/10.1016\/j.pan.2017.09.008","DOI":"10.1016\/j.pan.2017.09.008"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"[20] Jarosova J, Macinga P, Krupickova L, Fialova M, Hujova A, Mares J, Urban O, Hajer J, Spicak J, Striz I, Hucl T. Impact of endoluminal radiofrequency ablation on immunity in pancreatic cancer and cholangiocarcinoma. Biomedicines, 2022, 10(6):1331. https:\/\/doi.org\/10.3390\/biomedicines10061331","DOI":"10.3390\/biomedicines10061331"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"[21] Dromi SA, Walsh MP, Herby S, Traughber B, Xie J, Sharma KV, Sekhar KP, Luk A, Liewehr DJ, Dreher MR, Fry TJ, Wood BJ. Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity. Radiology, 2009, 251(1):58-66. https:\/\/doi.org\/10.1148\/radiol.2511072175","DOI":"10.1148\/radiol.2511072175"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"[22] den Brok MHMGM, Sutmuller RPM, van der Voort R, Bennink EJ, Figdor CG, Ruers TJM, Adema GJ. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res, 2004, 64(11):4024-4029. https:\/\/doi.org\/10.1158\/0008-5472.CAN-03-3949","DOI":"10.1158\/0008-5472.CAN-03-3949"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"[23] Hofland J, Falconi M, Christ E, Casta\u00f1o JP, Faggiano A, Lamarca A, Perren A, Petrucci S, Prasad V, Ruszniewski P, Thirlwell C, Vullierme MP, Welin S, Bartsch DK. European Neuroendocrine Tumor Society 2023 Guidance Paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol, 2023, 35(8):e13318. https:\/\/doi.org\/10.1111\/jne.13318","DOI":"10.1111\/jne.13318"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"[24] Crin\u00f2 SF, Napoleon B, Facciorusso A, Lakhtakia S, Borbath I, Caillol F, Do-Cong Pham K, Rizzatti G, Forti E, Palazzo L, Belle A, Vilmann P, van Laethem JL, Mohamadnejad M, Godat S, Hindryckx P, Benson A, Tacelli M, De Nucci G, Binda C, Kovacevic B, Jacob H, Partelli S, Falconi M, Salvia R, Landoni L; ERASING study collaborators; Larghi A. Endoscopic ultrasound-guided radiofrequency ablation versus surgical resection for treatment of pancreatic insulinoma. Clin Gastroenterol Hepatol, 2023, 21(11):2834-2843.e2. https:\/\/doi.org\/10.1016\/j.cgh.2023.02.022","DOI":"10.1016\/j.cgh.2023.02.022"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"[25] El Sayed G, Frim L, Franklin J, McCrudden R, Gordon C, Al-Shamma S, Kiss S, Hegyi P, Er\u0151ss B, Hegyi PJ. Endoscopic ultrasound-guided ethanol and radiofrequency ablation of pancreatic insulinomas: a systematic literature review. Therap Adv Gastroenterol, 2021, 14:17562848211042171. https:\/\/doi.org\/10.1177\/17562848211042171","DOI":"10.1177\/17562848211042171"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"[26] Rimba\u015f M, Dumitru AC, Tripodi G, Larghi A. EUS-guided radiofrequency ablation therapy for pancreatic neoplasia. Diagnostics (Basel), 2024, 14(19):2111. https:\/\/doi.org\/10.3390\/diagnostics14192111","DOI":"10.3390\/diagnostics14192111"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"[27] Marx M, Godat S, Caillol F, Poizat F, Ratone JP, Pesenti C, Schoepfer A, Hoibian S, Dahel Y, Giovannini M. Management of non-functional pancreatic neuroendocrine tumors by endoscopic ultrasound-guided radiofrequency ablation: retrospective study in two tertiary centers. Dig Endosc, 2022, 34(6):1207-1213. https:\/\/doi.org\/10.1111\/den.14224","DOI":"10.1111\/den.14224"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"[28] Oleinikov K, Dancour A, Epshtein J, Benson A, Mazeh H, Tal I, Matalon S, Benbassat CA, Livovsky DM, Goldin E, Gross DJ, Jacob H, Grozinsky-Glasberg S. Endoscopic ultrasound-guided radiofrequency ablation: a new therapeutic approach for pancreatic neuroendocrine tumors. J Clin Endocrinol Metab, 2019, 104(7):2637-2647. https:\/\/doi.org\/10.1210\/jc.2019-00282","DOI":"10.1210\/jc.2019-00282"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"[29] Lesmana CRA. Endoscopic loco-regional treatment in controlling pancreatic neuroendocrine tumors (PNETs) behavior: a case series and literature review. Clin J Gastroenterol, 2024, 17(4):754-759. https:\/\/doi.org\/10.1007\/s12328-024-01959-2","DOI":"10.1007\/s12328-024-01959-2"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"[30] Khoury T, Sbeit W, Fusaroli P, Campana D, Brighi N, Napoleon B, Lisotti A. Safety and efficacy of endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine neoplasms: systematic review and meta-analysis. Dig Endosc, 2024, 36(4):395-405. https:\/\/doi.org\/10.1111\/den.14681","DOI":"10.1111\/den.14681"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"[31] Fahmawi Y, Mehta A, Abdalhadi H, Merritt L, Mizrahi M. Efficacy and safety of endoscopic ultrasound-guided radiofrequency ablation for management of pancreatic lesions: a systematic review and meta-analysis. Transl Gastroenterol Hepatol, 2022, 7:30. https:\/\/doi.org\/10.21037\/tgh-20-84","DOI":"10.21037\/tgh-20-84"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"[32] Napol\u00e9on B, Lisotti A, Caillol F, Gasmi M, Ah-Soune P, Belle A, Charachon A, Chevaux JB, Cholet F, Eyraud PY, Grandval P, Koch S, Le Rhun M, Mangialavori L, Musquer N, Palazzo M, Poincloux L, Privat J, Sosa-Valencia L, Adrien S, Stouvenot M, Habersetzer F, Subtil C, Thomassin L, Vanbiervliet G, Vidal G, Vuitton L, Giovannini M, Gonzalez JM, Barthet M. OP031 Safety and efficacy of endoscopic ultrasound-guided radiofrequency ablation for pancreatic neoplasms - a 2-year retrospective French multicenter study. 30th United European Gastroenterology (UEG) Week, Vienna, Austria, October 8-11, 2022, Oral Presentations, United Eur Gastroenterol J, 2022, 10(S8):31. https:\/\/doi.org\/10.1002\/ueg2.12293","DOI":"10.1002\/ueg2.12293"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"[33] Partelli S, Massironi S, Zerbi A, Niccoli P, Kwon W, Landoni L, Panzuto F, Tomazic A, Bongiovanni A, Kaltsas G, Sauvanet A, Bertani E, Mazzaferro V, Caplin M, Armstrong T, Weickert MO, Ramage J, Segelov E, Butturini G, Staettner S, Cives M, Frilling A, Moulton CA, He J, Boesch F, Selberheer A, Twito O, Castaldi A, De Angelis CG, Gaujoux S, Holzer K, Wilson CH, Almeamar H, Vigia E, Muffatti F, Luc\u00e0 M, Lania A, Ewald J, Kim H, Salvia R, Rinzivillo M, Smid A, Gardini A, Tsoli M, Hentic O, Colombo S, Citterio D, Toumpanakis C, Ramsey E, Randeva HS, Srirajaskanthan R, Croagh D, Regi P, Gasteiger S, Invernizzi P, Ridolfi C, Giovannini M, Jang JY, Bassi C, Falconi M. Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial. Br J Surg, 2022, 109(12):1186-1190. https:\/\/doi.org\/10.1093\/bjs\/znac267","DOI":"10.1093\/bjs\/znac267"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"[34] Barthet M, Giovannini M, Lesavre N, Boustiere C, Napoleon B, Koch S, Gasmi M, Vanbiervliet G, Gonzalez JM. Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors and pancreatic cystic neoplasms: a prospective multicenter study. Endoscopy, 2019, 51(9):836-842. https:\/\/doi.org\/10.1055\/a-0824-7067","DOI":"10.1055\/a-0824-7067"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"[35] Armellini E, Facciorusso A, Crin\u00f2 SF. Efficacy and safety of endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors: a systematic review and metanalysis. Medicina (Kaunas), 2023, 59(2):359. https:\/\/doi.org\/10.3390\/medicina59020359","DOI":"10.3390\/medicina59020359"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"[36] Marx M, Trosic-Ivanisevic T, Caillol F, Demartines N, Schoepfer A, Pesenti C, Ratone JP, Robert M, Giovannini M, Godat S. EUS-guided radiofrequency ablation for pancreatic insulinoma: experience in 2 tertiary centers. Gastrointest Endosc, 2022, 95(6):1256-1263. https:\/\/doi.org\/10.1016\/j.gie.2021.11.045","DOI":"10.1016\/j.gie.2021.11.045"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"[37] Biermann MR, Sundar P, Veeramachaneni H, Chawla S, Patel V, Orr J, Keilin S, Willingham FF. Radiofrequency ablation for the management of symptomatic pancreatic insulinomas. VideoGIE, 2023, 9(1):45-50. https:\/\/doi.org\/10.1016\/j.vgie.2023.08.007","DOI":"10.1016\/j.vgie.2023.08.007"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"[38] Larghi A, Rizzatti G, Rimba\u015f M, Crino SF, Gasbarrini A, Costamagna G. EUS-guided radiofrequency ablation as an alternative to surgery for pancreatic neuroendocrine neoplasms: who should we treat? Endosc Ultrasound, 2019, 8(4):220-226. https:\/\/doi.org\/10.4103\/eus.eus_28_19\"","DOI":"10.4103\/eus.eus_28_19"}],"container-title":["Romanian Journal of Morphology and Embryology"],"original-title":[],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T08:44:59Z","timestamp":1748594699000},"score":1,"resource":{"primary":{"URL":"https:\/\/rjme.ro\/archive\/66\/1\/2\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,15]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,5,15]]},"published-print":{"date-parts":[[2025,5,23]]}},"URL":"https:\/\/doi.org\/10.47162\/rjme.66.1.02","relation":{},"ISSN":["1220-0522","2066-8279"],"issn-type":[{"value":"1220-0522","type":"print"},{"value":"2066-8279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,15]]}}}